Modality
mRNA
MOA
DLL3 ADC
Target
CD47
Pathway
Cell Cycle
SchizophreniaRett
Development Pipeline
Preclinical
~Nov 2017
→ ~Feb 2019
Phase 1
~May 2019
→ ~Aug 2020
Phase 2
Nov 2020
→ Mar 2030
Phase 2Current
NCT05750333
801 pts·Schizophrenia
2020-11→2025-08·Not yet recruiting
NCT03849130
2,260 pts·Rett
2021-10→2030-03·Active
3,061 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-08-018mo agoPh3 Readout· Schizophrenia
2030-03-123.9y awayPh3 Readout· Rett
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P2/3
Not yet…
P2/3
Active
Catalysts
Ph3 Readout
2025-08-01 · 8mo ago
Schizophrenia
Ph3 Readout
2030-03-12 · 3.9y away
Rett
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05750333 | Phase 2/3 | Schizophrenia | Not yet recr... | 801 | NT-proBNP |
| NCT03849130 | Phase 2/3 | Rett | Active | 2260 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| Rimamavacamten | Merck & Co | Phase 1 | PI3Kα | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| BMR-1165 | BioMarin | Phase 2 | CD47 | |
| INC-2432 | Incyte | Phase 2 | CD47 | |
| Cevifotisoran | Neurocrine | Approved | CD47 | |
| Pemiinavolisib | Sarepta | NDA/BLA | CD47 |